Stock RV6 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Charles River Laboratories International, Inc. Börse Stuttgart

Equities

RV6

US1598641074

Market Closed - Börse Stuttgart
Other stock markets
 09:26:11 31/05/2024 pm IST 		5-day change 1st Jan Change
191.2 EUR -1.24% Intraday chart for Charles River Laboratories International, Inc. -4.11% -10.09%
30/05 Charles River Laboratories International, Inc. Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development CI
15/05 Transcript : Charles River Laboratories International, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • With a 2024 P/E ratio at 26.35 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-10.09% 1.07TCr -
MODERNA, INC. Stock Moderna, Inc.
+43.36% 5.46TCr
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 3.99TCr
B
LONZA GROUP AG Stock Lonza Group AG
+37.52% 3.88TCr
A
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 2.69TCr
B-
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 2.62TCr
C
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 1.88TCr
B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 1.22TCr
B+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 1.22TCr
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 1.19TCr
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. CRL Stock
  4. RV6 Stock
  5. Ratings Charles River Laboratories International, Inc.